On 12 August 2026 Eli Lilly and Company filed six US lawsuits against businesses it accuses of selling black-market versions of retatrutide, its investigational triple agonist. The filings are the company's most aggressive step yet against unauthorised sellers of a compound that has not been approved by any regulator — and they sit alongside continuing UK enforcement against unlicensed weight-loss peptides.
1. What Lilly filed
The company said the six suits target a compounding pharmacy, a medical spa and online sellers, including several that market products as 'research-use only'. According to Reuters, the named defendants include Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide.
Lilly said it has referred more than 200 individuals and entities to the US Food and Drug Administration, the Department of Justice, state attorneys general, law enforcement and professional licensing boards, and has reported more than 14,000 websites, advertisements, social media posts and product listings to platforms across more than 100 countries. It also called on social media and e-commerce platforms, payment processors, card networks and shipping firms to act against sellers.
2. Why retatrutide's status is central
Retatrutide is not licensed anywhere. It remains in Phase 3 trials for obesity, type 2 diabetes and related conditions. In the UK it has no MHRA marketing authorisation and is not available for routine prescribing; legitimate access is limited to participation in authorised clinical trials. Any product sold as retatrutide outside that setting is an unlicensed medicinal product, and its supply would engage the Human Medicines Regulations 2012.
That legal position is the same in substance for every unapproved research peptide. What is unusual here is the commercial pressure being applied to enforce it.
3. The UK dimension
UK enforcement has run through the regulator rather than the courts. On 25 February 2026 the MHRA's Criminal Enforcement Unit raided two premises in Lincolnshire and Nottinghamshire and seized almost 2,000 doses of unauthorised weight-loss medicines awaiting dispatch, including retatrutide and tirzepatide, along with manufacturing equipment and vehicles.
The direction of travel is the same on both sides of the Atlantic: unlicensed GLP-1 peptides are moving from a grey-market nuisance to a priority enforcement target. Readers should treat any offer of retatrutide outside a trial as both unlicensed in the UK and, increasingly, actively pursued.
4. The 'research-use only' question
Several defendants in the Lilly suits are described as research-use-only sellers. The FDA has stated that sales of unapproved retatrutide to consumers are illegal and that so-called research-use-only products 'are of unknown quality and may be harmful'. The UK position is parallel: as the MHRA has made clear in the context of peptide clinics, a research-purposes label is disregarded where it is being used to avoid medicines regulation.
For genuine laboratory procurement, the distinction is not the label alone but the consistency of intended use and the absence of consumer-directed therapeutic claims.
5. What this does not change
The lawsuits are a US civil matter and do not alter UK law. They do not change the regulatory status of retatrutide, other GLP-1 peptides or any research compound, and they are not evidence about efficacy or safety. Their significance is enforcement and supply risk: they signal that manufacturers will pursue sellers of unapproved peptides directly.
Peptide Data makes no therapeutic claims and provides no consumption, dosing or self-administration guidance. Retatrutide and the other compounds named are research-use-only.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.